Advanced Liver Cancer Clinical Trial
Official title:
A Phase 1, Open-Label Study of ABSK-011 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Solid Tumors
This is an open-label phase 1 study with an escalation part and an expansion part.
The escalation part will evaluate the safety, tolerability, PK and recommended dose of expansion (RDE) of oral ABSK-011 in patients with advanced solid tumors. The expansion part of oral ABSK-011 at RDE will be followed for further evaluating safety and tolerability in patients with FGF19 overexpression advanced HCC. Preliminary antitumor activity will also be assessed. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01754987 -
A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05698459 -
OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients With Advanced Liver Cancer
|
Phase 1 | |
| Recruiting |
NCT03146637 -
Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer
|
Phase 2 | |
| Withdrawn |
NCT03484962 -
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer
|
Phase 2 | |
| Recruiting |
NCT05603039 -
A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04163237 -
Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer
|
Phase 3 | |
| Recruiting |
NCT02862613 -
Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02873442 -
Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03474822 -
Plasmodium Immunotherapy for Breast and Liver Cancers
|
Phase 1/Phase 2 |